Delivery Order 75N93025D00006-75N93026F00001
- Not listed
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a Firm Fixed Price Purchase Order contract to Asischem Inc. to provide custom synthesis of a chemical compound. The contract, valued at $4,890.00, was awarded on August 3, 2015 with a completion date of December 1, 2015. This contract was not set aside for any specific business type or size. Based on the agency name, this contract is likely related to NIAID's research and development programs focused on infectious...
- This is a firm fixed-price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute in Seattle, Washington. The contract is for in vitro characterization of anti-mycobacterial activity, as part of the larger In Vitro Antimicrobial Assessments 2011-2018 contract vehicle. The contract has a ceiling value of...
- This federal contract award, with an ID of HHSN272201600571P, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS). The contract, valued at $9,500.00, was awarded to Chem-Master International, Inc., a research, development, and manufacturing company, for the delivery of AMINOPROPYL TRISACCHARIDE 1. The contract was a Firm Fixed Price purchase order, with a period of performance ending on May 2,...
- Curia Global Inc., doing business as Amri, has been awarded a $620,125 delivery order against the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases' Nonclinical Services for Development of Interventional Agents indefinite-delivery/indefinite-quantity contract. The delivery order is for scale-up synthesis of APX2039, a novel GWT1 enzyme inhibitor in fungi, in support of NIH's efforts to develop new treatments for...
- This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute. The $4,140 contract is for infectious disease research functions and does not have a set-aside designation. AAHI, which also operates under the names Aahi, Idri, and Infectious Disease Research Institute, conducts research and...
- The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $49,946.10 firm-fixed-price purchase order contract for antibody expression services to Biointron Biological USA Inc., a small disadvantaged business. The contract, which has no set-aside designation, has an ultimate completion date of July 11, 2025. The award was made on July 12, 2024. NIAID is responsible for conducting and supporting research to understand, treat, and prevent infectious and...
- The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $780,764 firm fixed price purchase order contract to Access To Advanced Health Institute, doing business as Aahi, Idri, Infectious Disease Research Institute, located in Rockville, Maryland. Under the contract, Idri will provide investigational products GLA-SE adjuvant formulation and lyophilized ID93 from Idri for clinical trials funded by NIAID's Division of AIDS. As the prime contractor, Idri...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $21.6 million to PPD Development LP for Division of AIDS (DAIDS) monitoring services supporting the Phase III PHOENIX study (A5300B/I2003B). This contract, awarded December 15, 2025, with an ultimate completion date of December 14, 2028, will be performed in Cape Fear, North Carolina. The award utilizes a cost-plus-fixed-fee pricing structure with no set-aside designation and represents a child...
- This is a federal contract award to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute located in Seattle, Washington. The contract, titled "PANACEA", is a non-set-aside Other Transaction Agreement with a ceiling value of $2,854,631.10 and an ultimate completion date of August 29, 2024. AAHI, doing business as Aahi, Idri, and Infectious Disease Research Institute, is a prime contractor experienced in conducting research and development of vaccine...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, has awarded a $547,287.76 Delivery Order to Axle Informatics, LLC, a certified Women-Owned Small Business. This Delivery Order is issued under the NIAID Professional, Scientific and Technical Support Services master IDIQ contract. The contract provides professional, scientific, and technical support services for the NIAID Division of Intramural Research...
- 75N93025D00006Indefinite Delivery Contract
- 75N93025D00006-75N93026F00001Delivery Order
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order contract to Aapharmasyn LLC (doing business as AAP) on January 30, 2026, for interventional agents chemistry services under Task Area B of a base indefinite delivery/indefinite quantity (IDIQ) contract. The award carries a ceiling value of $147,236 with a firm fixed price structure and is scheduled for completion by July 29, 2026. The work will be performed in Ann Arbor, Michigan. No set-aside designation was applied to this award. Aapharmasyn LLC is a small business entity that specializes in experimental therapeutics medicinal chemistry, focusing on research and development services in medicinal chemistry and related support. The company operates as a child entity and has established a track record delivering chemistry and research services to federal agencies. NIAID's selection of the contractor for interventional agents chemistry services aligns with the institute's research mission in infectious diseases and immunology, leveraging specialized medicinal chemistry expertise to support drug development and evaluation efforts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $147.2k | 1/27/26 |